CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients

Daniel Baumhoer; Mareike Elsner; Jan Smida; Stephanie Zillmer; Sandra Rauser; Cédrik Schoene; Benjamin Balluff; Stefan Bielack; Gernot Jundt; Axel Walch; Michaela Nathrath

doi:10.18632/oncotarget.398

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Brief Reports:

CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients

Daniel Baumhoer _, Mareike Elsner, Jan Smida, Stephanie Zillmer, Sandra Rauser, Cédrik Schoene, Benjamin Balluff, Stefan Bielack, Gernot Jundt, Axel Walch and Michaela Nathrath

PDF | HTML | How to cite

Oncotarget. 2011; 2:970-975. https://doi.org/10.18632/oncotarget.398

Metrics: PDF 2817 views | HTML 3214 views | ?

Abstract

Daniel Baumhoer^1,2,*, Mareike Elsner^3,*, Jan Smida^2,4, Stephanie Zillmer², Sandra Rauser³, Cédrik Schoene³, Benjamin Balluff³, Stefan Bielack⁵, Gernot Jundt¹, Axel Walch^3,#, and Michaela Nathrath^2,4,#

¹ Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, Basel, Switzerland

² Clinical Cooperation Group Osteosarcoma, Helmholtz Zentrum Muenchen - National Research Centre for Environment and Health, Neuherberg, Germany

³ Institute of Pathology, Helmholtz Zentrum Muenchen - National Research Centre for Environment and Health, Neuherberg, Germany

⁴ Department of Pediatrics, Technische Universitaet Muenchen and Pediatric Oncology Center, Munich, Germany

⁵ Klinikum Stuttgart Olgahospital, Pediatrics 5 - Oncology, Hematology, Immunology, Stuttgart, Germany

^* Denotes equal contribution

^# Shared senior authorship

Received: December 21, 2011; Accepted: December 23, 2011; Published: December 24, 2011;

Keywords: Osteosarcoma, cysteine-rich intestinal protein 1, CRIP1, prognosis, metastases

Correspondence:

Daniel Baumhoer, email:

Abstract

Predicting the clinical course of osteosarcoma patients is a crucial prerequisite for a better treatment stratification in these highly aggressive neoplasms of bone. In search of new and reliable biomarkers we recently identified cysteine-rich intestinal protein 1 (CRIP1) to have significant prognostic impact in gastric cancer and therefore decided to investigate its role also in osteosarcoma. For this purpose we analyzed 223 pretherapeutic and well characterized osteosarcoma samples for their immunohistochemical expression of CRIP1 and correlated our findings with clinico-pathological parameters including follow‑up, systemic spread and response to chemotherapy. Interestingly and contrarily to gastric cancer, we found CRIP1 expression more frequently in patients with long‑term survival (10-year survival 73% in positive vs. 54% in negative cases, p = 0.0433) and without metastases (p = 0.0108) indicating a favorable prognostic effect. CRIP1 therefore seems to represent a promising new biomarker in osteosarcoma patients which should be considered for a prospective validation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 398

Publication Alerts

Brief Reports:

CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients

Abstract